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Evaluating clinical and laboratory 
effects of ozone in non-surgical 
periodontal treatment: a randomized 
controlled trial
Objective: This study aims to evaluate the clinical and biochemical 
(oxidative stress and pro-inflammatory mediators) effects of the gaseous 
ozone use accompanied by scaling and root planning (SRP) in periodontal 
treatment. Material and Methods: The study population consisted of 40 
patients with chronic periodontitis (CP) randomly sorted into two groups 
of 20. The experimental group received SRP plus 3 watts gaseous ozone 
in two separate applications five days apart, whereas the control group 
received SRP plus placebo. Clinical periodontal parameters were assayed 
and saliva samples were taken before the initial and one month after the 
second treatment. Periodontal examination assessed plaque index (PI), 
gingival index (GI), probing depth, and clinical attachment level (CAL). 
Total antioxidant status (TAS), total oxidant status (TOS), nitric oxide 
(NO), 8-hydroxy-2'-deoxyguanosine (8-OHdG), myeloperoxidase (MPO), 
glutathione (GSH), malondialdehyde (MDA), and transforming growth factor-
beta (TGF-β) levels were evaluated from saliva samples. Results: Changes 
following treatment in PI, GI, probing depth, and CAL scores were similar 
for both groups (p>0.05). Of note, TGF-β levels were observed to be higher 
in the treatment group than in controls (p<0.05). Changes in 8-OHdG, 
TAS, TOS, NO, MPO, GSH and MDA levels, however, were not significantly 
different between groups (p>0.05). Conclusion: The findings of this study 
indicate that SRP plus gaseous ozone versus SRP alone does not correlate 
to a significant improvement in periodontal recovery.
Keywords: Chronic periodontitis. Inflammation. Ozone. Periodontal 
treatment. TGF-β.
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Introduction
The complicated interaction between the immune 
inflammatory response and periodontopathogenic 
bacteria usually results in chronic periodontitis (CP). 
In clinical terms, CP is characterized by periodontal 
pockets, gingival inflammation, and loss of attachment 
to and in the alveolar bone, which can eventually lead 
to tooth loss.1 A network of interacting molecular 
pathways involving proinflammatory mediators 
and reactive oxygen species (ROS) are involved in 
the progression of periodontal disease (PD).2 An 
increase in cytokine expression and immunological 
activity in gingival tissues occurs with this interaction 
between the host immune system and pathogenic 
bacteria, and proinflammatory mediators facilitate the 
immune response to periodontopathic bacteria. Local 
cytokine production, which develops in response to 
periodontal infection, may also influence the systemic 
environment. Tumor Necrosis Factor-α (TNFα) and 
Interleukin 6 (IL-6) are key cytokines for the initiation 
and maintenance of the systemic inflammation 
involved in the progression and severity of PD.3
Pathogenic mechanisms of the disease may involve 
antioxidant (AO) activity and oxygen-dependent 
ROS production. A study conducted by Chapple, 
et al.4 (1997) correlated PD with reduced salivary 
AO status, and increased oxidative damage in the 
oral cavity. Other studies have examined a possible 
relation between PD, reduced salivary AO status, and 
increased oxidative damage.5,6 An increase in levels of 
8-hydroxy-2’-deoxyguanosine (8-OHdG), a biomarker 
of oxidative stress, has also been reported to be 
associated with periodontitis.7
Treatments for periodontitis focus on reducing 
pathogens embedded in the subgingival biofilm.8 
Modalities range from oral hygiene instruction, 
non-surgical periodontal treatment (NSPT), and 
supra- and subgingival debridement, to periodontal 
surgery. NSPT may be applied by hand or via 
powered instrumentation. Studies conducted thus 
far indicate that NSPT reduces tooth loss risk, slows 
PD progression rate, and enhances gingival health, 
and NSPT is considered an indispensable therapy 
component against inflammatory PD.9 However, 
effectiveness of NSPT is limited in certain areas, such 
as difficulty to reach and deep pockets.10 The use of 
laser or ozone has been discussed as an alternative 
to this process, and recent reports include the use 
of ozone in dentistry as an alternative oral antiseptic 
component.11 According to recent studies, gaseous 
and aqueous forms of ozone have high antimicrobial 
power against oral pathogens and are impervious to 
resistance.12
Between 1880 and 1932, the ozone therapy 
method was widely used as an alternative medication 
in the United States, and many countries currently 
accept ozone therapy as a treatment modality.13 
Ozone is an unstable matrix of three oxygen atoms 
(O3), and has been shown to be an impressive 
antiviral and antifungal agent.14 It has been used 
as a therapeutic agent for chronic wounds (e.g., 
trophic and ischemic ulcers, diabetic wounds, etc.) 
in several empirical studies.15,16 The use of ozone 
has been examined for efficacy against viral, fungal, 
and bacterial infections; ocular, ischemic, orthopedic, 
hematological, neurodegenerative, pulmonary, renal, 
and dermatological diseases; and age-dependent 
macular degeneration.17,18 Existing uses of both gaseous 
and aqueous forms of ozone in dentistry include 
inhibition of bacterial proliferation, enhancement of 
epithelial wound healing, enhancement of local oxygen 
supply, elimination of pathogen caries, root canal 
disinfection, and promotion of hemostasis.19-21 While 
laboratory studies suggest promise for ozone in the 
treatment of periodontal disease, clinical evidence is 
extremely limited. This study aims to evaluate the 
clinical and biochemical (oxidative stress and pro-
inflammatory mediators) effects of the use of gaseous 
ozone in addition to scaling and root planning (SRP) 
in periodontal treatment.
Materials and methods
Study population
We utilized a randomized, parallel controlled, and 
double-blinded design in a full-mouth clinical trial with 
a follow up at one-month post-treatment. The Ethics 
Committee approved the study protocol in accordance 
with the Helsinki Declaration. This study was registered 
at ClinicalTrials.gov (NCT03444350). Written informed 
consent was obtained from all participants. Patients 
were selected from the Department of Periodontology 
patient pool. Forty patients with generalized to 
moderate CP were included in the study. Median age 
of patients was 42.4, within a deviation of ±6.7 years.
Sample-size estimation for this study was based on 
clinical attachment level (CAL), and it was determined 
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that each group should be composed of 18 subjects. 
The test was calculated to provide 80% power, 
detecting differences of 0.5 mm within an SD of 0.6 
mm. Two additional subjects were included per group 
(total 20) to compensate for possible dropouts during 
the study period.
To be included, patients were required to have 
generalized CP as agreed upon by consensus at the 
World Workshop in Periodontics in 1999;22 that is, three 
or more teeth having probing depth between 4 and 
6 mm, in at least two quadrants, with radiographic 
signs of bone loss, and a minimum of 20 teeth. 
Patients who had received periodontal therapy within 
the last 12 months, had systemic disease which could 
affect periodontal treatment outcomes, or had taken 
systemic antibiotics within the last 6 months were 
excluded. Pregnant or breast-feeding patients were 
also excluded.
Treatment protocol
SRP plus gaseous ozone [3 W, (n=20)] was applied 
to the experimental group. The control group (n=20) 
received SRP plus placebo. Patients were randomly 
distributed between the two groups. One patient in 
the treatment group and two in the control group left 
the study prior to completion.
Participants were provided with detailed information 
on oral hygiene (including self-performed plaque control 
measures, and inter-dental cleaning maintenance with 
the help of flossing and toothbrushing) two weeks 
before treatment. Full-mouth supragingival and 
subgingival SRP was applied under local anesthesia, 
both by hand (Hu-Friedy, Chicago, IL, USA) and with 
ultrasonic instruments. Ozone was then applied to the 
periodontal pockets of patients in the experimental 
group in accordance with the manufacturer’s protocol 
(Ozone DTA, Apoza Enterprise Co., New Taipei, 
Taiwan, R.O.C.) (Figure 2). Ozone application for 
each tooth was performed twice, on days 3 and 8, 
following periodontal treatment (Figure 1). Ozone was 
administered in the gingival sulcus of all teeth with a 
thin glass tip, moving in the apical-coronal direction 
in a sweeping motion, and applied to mesial, distal, 
buccal, and lingual surfaces in a one-minute period. 
The device was applied without ozone (placebo) in 
the control group.
Randomization of the study
Forty patients were distributed randomly between 
the two treatment groups. One researcher maintained 
the randomization list until patients were found to be 
eligible for the study. The clinician who performed the 
therapy was not informed about the modality of the 
treatment until the beginning of the first session for 
each patient. Results were evaluated blindly before and 
Figure 1- Research outline
Figure 2- Ozone device used in the study
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after treatment. Clinical measurements for all patients 
were made by an examiner who was not involved in 
providing treatment during the study. Before the start 
of the study, the examiner was trained to perform 
adequate levels of accuracy and reproducibility in 
recording clinical parameters and indices.
Clinical examination
One month after the second ozone application, 
plaque index (PI),23 gingival index (GI),24 probing 
depth, and CAL were recorded for each patient. 
A manual periodontal probe (PCP-12, Hu-Friedy, 
Chicago, IL, USA) was used for all clinical parameter 
measurements.
Saliva collection and laboratory assessments
Saliva samples from all patients were taken via 
expectoration before treatment and one month after 
the second treatment application (ozone or placebo). 
Paraffin wax-stimulated, whole saliva samples were 
obtained from patients in a quiet room during clinical 
examination between 0900 and 1200, eight hours 
prior to food intake. Approximately 2 mL of whole 
saliva sample was collected in disposable tubes and 
immediately centrifuged at 1,000g for 10 minutes to 
remove cell debris. Supernatant was removed and 
stored in small aliquots at −80°C until analysis. Total 
antioxidant status (TAS), total oxidant status (TOS), 
nitric oxide (NO), 8-OHdG, myeloperoxidase (MPO), 
glutathione (GSH), malondialdehyde (MDA), and 
transforming growth factor-beta (TGF-β) levels were 
evaluated.
Photometric kits (Rel Assay Diagnostics Co., 
Gaziantep, Turkey) were used to determine TAS and 
TOS in the saliva samples according to manufacturer’s 
directives. TOS results were given in terms of 
micromolar hydrogen peroxide equivalent per liter 
(μmol H2O2 equiv/L) and TAS results as mmol Trolox 
equiv/L.
Saliva 8-OHdG, TGF-β, and MPO levels were 
measured by enzyme-linked immunosorbent assay 
(ELISA) method. ELISA kits for TGF-β and MPO were 
purchased from Cayman Chemical Company (Cayman 
Chemical, Ann Arbor, HI, USA), and the ELISA kit 
for 8-OHdG was purchased from MyBioSource Inc. 
(MyBioSource, San Diego, CA, USA). 8-OHdG, MPO, 
and TGF-β levels in saliva samples were analyzed 
according to manufacturer’s instructions. All ELISA 
analyses were performed on a Brio-SEAC semi-
automatic ELISA machine (Radim Co., Calenzeno-
Firenze, Italy).
MDA levels in saliva samples were examined 
using Uchiyama and Mihara method. In brief, 
spectrophotometric results measurements of the 
reaction between MDA and thiobarbituric acid were 
taken at 535 nm and stated as nmol/L.
Saliva NO levels were measured by Cortas’ method, 
wherein spectrophotometric color density resulting 
from the reduction of nitrate to nitrite by cadmium is 
measured at 545 nm and expressed in µmol/L.
Saliva GSH values were calculated by the 
method developed by Fairbanks and Clee; that is, 
spectrophotometric measurement of the color resulting 
from the reaction between sulfhydryl groups and 
Elman’s reagent at 410 nm. Values are expressed as 
µmol/L.
Statistical analyses
Data was analyzed using SPSS software version 
17.0 for Windows. Means and standard deviations 
were calculated, and p values <0.05 were considered 
statistically significant. Shapiro-Wilk tests were 
computed for each variable to assess whether the 
variables were distributed normally. Student’s t-tests 
were used to determine the significance of differences 
in clinical parameters between groups. Differences in 
laboratory findings between groups were analyzed 
by the Mann-Whitney U-test. Wilcoxon tests were 
administrated to explore differences within groups.
Results
Socio-demographic characteristics of the study 
participants are shown in Table 1. No significant 
differences among participants were found in terms 
of gender, mean age, smoking rate and educational 
status.
Baseline clinical measurements were similar for 
Test Group
n=19
Control Group
n=18
p
Female/Male (n)   8/11 8/10 NS
Mean age
(years, mean±SD)
44.7±5.1 45.8±5.6 NS
Smoking (n) (yes) 10 9 NS
Education
(years, mean±SD)
10.6±2.7 9.9±3.0 NS
Table 1- Characteristics of the subjects
NS=not significant.
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both groups. Postoperative improvement in all clinical 
parameters was noted for both groups (p<0.05). 
After treatment, changes in the PI, GI, probing depth, 
and CAL were also similar for both groups (p>0.05) 
(Table 2).
Baseline laboratory findings were similar for both 
groups (p>0.05). The increase of MPO and TAS was 
observed in both groups after treatment (p<0.05). 
However, the increase of TGF-β levels was significantly 
greater in the test group compared with controls 
(p<0.05). Levels of 8-OHdG decreased in both groups 
after treatment (p<0.05) (Table 3).
Changes in 8-OHdG, GSH, MDA, MPO, TAS, TOS, 
and NO levels were similar between groups (p>0.05). 
Statistically significant differences between the ozone 
and control groups were limited to TGF-β levels 
following treatment (p<0.05) (Table 3).
Discussion
This is the first study to evaluate both clinical 
and biochemical in vivo effects of gaseous ozone on 
oxidative stress (TAS and TOS) and TGF-β, a marker 
for periodontal recovery. Ozone was applied in addition 
to noninvasive periodontal treatment. Levels of MDA, a 
lipid peroxidation end product; GSH, an AO molecule; 
8-OHdG, a marker of purin oxidation product; and NO, 
an oxidant agent were assessed. Results showed that 
the application of gaseous ozone was not associated 
with significant changes in periodontal recovery. 
Primary goals for the treatment of PD are the recycling 
Baseline One-month 
after 
treatment
Change p
PI 
Test Group 2.5±0.6 0.6±0.2 1.9 0.0003
Control Group 2.4±0.6 0.6±0.2 1.8 0.0003
p N.S. NS
GI
Test Group 2.3±0.7 0.8±0.2 1.4 0.0006
Control Group 2.1±0.6 0.9±0.2 1.2 0.0009
p NS NS
Probing depth
Test Group 3.8±0.8 3.0±0.6 0.8 0.008
Control Group 3.6±0.8 3.0±0.8 0.6 0.009
p NS NS
CAL
Test Group 4.4±1.1 4.0±0.7 0.4 0.03
Control Group 4.1±0.8 3.8±0.8 0.3 0.03
p NS NS
Table 2- The compared inter- and intragroup clinical findings at 
baseline and one month after treatment (mean±SD)
PI=plaque index; GI=gingival index; CAL=clinical attachment 
level
NS=not significant
p<0.05; statistically significant
Baseline One-month 
after 
treatment
Change p
8 OHdG 
Test Group 1331±451 1045±309 -286 0.008
Control Group 1626±502 1324±327 -302 0.008
p NS       0.047
GSH 
Test Group 30.9±14.7 35.1±17.2 4.2 NS
Control Group 29.6±14.9 34.2±16.5 4.6 NS
p NS
MDA
Test Group 23.4±8.1 18.0±7.3 -5.4 NS
Control Group 20.6±7.9 16.9±7.9 -3.7 NS
p NS N.S.
MPO
Test Group 752±294 854±306 102 0.042
Control Group 651±304 761±354 100 0.038
p NS NS
TAS
Test Group 4.33±1.1           
4.72±1.2
0.39 0.038
Control Group 4.01±1.0           
4.51±1.0
0.5 0.024
P NS                   NS
TOS
Test Group 16.2±5.5   15.5±5.6 0.7 NS
Control Group 17.3±6.1   15.3±6.0 2 NS
P                   NS
TGF- β
Test Group 42.7±11.6 48.4±11.1 5.7 0.031
Control Group 39.5±10.2 39.6±10.4 0.1 NS
P NS 0.026
NO
Test Group 24.5±9.8 20.9±6.1 3.6 NS
Control Group 23.3±8.6 20.0±6.6 3.3 NS
p NS N.S.
Table 3- The compared inter- and intra the groups of laboratory 
findings at baseline and at one month after treatment (mean±SD)
8-OHdG=8-hydroxy-2’-deoxyguanosine; GSH=glutathione; 
MDA=malondialdehyde; MPO=myeloperoxidase; TAS=total 
antioxidant status; TOS=total oxidant status; TGF-β=transforming 
growth factor beta; NO=nitric oxide
NS=not significant
p<0.05; statistically significant
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of attachment loss, the decrease in pocket depth, and 
the elimination of inflammation.25 In order to reach 
these goals, the first treatment option for patients 
whose pockets are not deep is non-surgical.26 However, 
the success of non-surgical treatment with hand tools 
and cavitron is limited where pockets are difficult to 
reach.10 In addition, the effectiveness of non-surgical 
treatment in tissue regeneration, a primary therapeutic 
target, is less than ideal. As such, changing the host 
immune response to oral pathogens and increasing the 
efficiency of treatment methods are desired markers 
for clinical success. Recently, ozone treatment has 
been hypothesized to increase tissue healing and 
periodontal recovery by decreasing oxidative stress 
and antibacterial characteristics. In this study, we 
aimed to assess the effectiveness of gaseous ozone 
on periodontal tissue recovery by examining clinical 
and laboratory findings.
The use of ozone in periodontal therapy is based 
on its antimicrobial, immunostimulating, anti-hypoxic, 
and biosynthetic properties.27 Ozone is theorized 
to contribute to periodontal healing by eliminating 
pathogens, activating the immune system, and 
stimulating the humoral antioxidant system;27 
however, clinical evidence thereto is limited. Most 
studies on this modality are carried out in vitro and 
few clinical trials have been done. We examined the 
clinical effects of ozone use in periodontal treatment 
using a randomized, double-blinded study design.
Nagayoshi, et al.28 (2004) have reported that 
ozonated water was effective in killing both gram-
positive and gram-negative oral microorganisms. 
They also reported that gram-negative anaerobes 
were more sensitive to ozonated water than gram-
positive anaerobes. Their study found that ozonated 
water could inhibit the accumulation of experimental 
dental plaque in vitro and reported that ozonated 
water had strong activity against bacteria found in 
plaque biofilms.27 Muller, et al.29 (2007) compared 
the efficiency of gaseous ozone versus photodynamic 
therapy on oral biofilms, however, they found that 
the use of ozone could not eliminate or reduce biofilm 
microbial populations. Huth, et al.11 (2007) studied the 
influence of ozone on the host immune response and 
concluded that NF-κB activity in periodontal ligament 
tissue from the root surfaces of periodontally damaged 
teeth was inhibited following incubation with ozonated 
media. In this context, Huth’s team contended that 
ozone application could induce anti-inflammatory 
effects.
Many recent studies have investigated the effects 
of ozonated water and SRP plus ozone applications. 
Ramzy, et al.30 (2005) did a study on 22 aggressive 
periodontitis patients wherein ozonated water was 
used to irrigate their periodontal pockets. Significant 
improvements in PI, GI, probing depth, and bacterial 
count were observed; however, they also reported 
statistically significant decreases in bacterial counts 
in areas that received ionized water treatment. 
Kshitish and Laxman31 (2010), in a study with 
generalized CP patients, irrigated one half of the 
mouth with ozonated water and the other half with 
0.2% chlorhexidine andreported better results with 
ozonated water compared to chlorhexidine irrigation 
in PI, GI, and bleeding indices. In a study conducted 
on CP patients by Yilmaz, et al.32 (2013), the effects 
of the Er:YAG laser and topical gaseous ozone 
application (as adjuncts to initial periodontal therapy) 
were clinically and microbiologically investigated; 
however, their results showed attachment gain and 
probing depth reduction at a statistically significant 
level in favor of the laser group, although intergroup 
comparisons of microbiological parameters showed no 
significant differences. Habashneh, et al.33 (2015), in 
another study on CP patients, reported no significant 
differences between SRP + irrigation with ozonated 
water versus SRP + irrigation with distilled water in 
terms of PI, GI, bacterial proliferation, probing depth, 
gingival recession, and CAL and serum CRP levels. 
Evidence regarding ozone application on clinical 
recovery, therefore, has been difficult to pin down.
Recent clinical studies have demonstrated 
that gaseous and aqueous forms of ozone have 
antimicrobial effects against oral pathogens linked 
with caries and endodontic infections. There have 
also been reports that ozone therapy decreases the 
growth of Aggregatibacter actinomycetemcomitans, 
Porphyromonas gingivalis, and Tannerella forsythia 
at statistically significant levels.34,35 Some studies, 
even in aggressive periodontitis patients, assaying 
SRP plus ozone have also demonstrated significant 
improvements in GI, pocket probing depths, PI, 
and bacterial counts.30,31 Hauser-Gerspach, et al.36 
(2012) examined the effects on bacteria adhered 
to titanium implant surface of gaseous ozone and 
reported decrease in bacterial counts in the surfaces 
that received ozone treatment.
Despite results in the literature suggesting 
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ozone might be influential in the elimination of 
periodontopathogenic bacteria, data regarding clinical 
recovery are not consistent with these findings. 
However, ozone application has been associated with 
increased bone and epithelial recovery.37,38 Based on 
these data, it might be expected that ozone could 
exert a positive influence on clinical recovery from 
PD. Our clinical results, however, indicated that ozone 
treatment was not correlated with additional benefits 
in clinical periodontal recovery within a one-month 
period.
Ozone has several positive effects on cellular and 
humoral immune system components, in stimulation 
of the proliferation of immunocompetent cells and 
synthesis of immunoglobulins.39 It has been well-
established that ozone activates macrophages 
and enhances the sensitivity of microorganisms to 
phagocytosis. Immune cells of the body produce 
certain cytokines as a response to the activation 
caused by ozone. Ozone triggers the synthesis of 
various biologically active substances that reduce 
inflammation and promote wound healing, such 
as interleukins, leukotrienes and prostaglandins. 
Oxidant and AO molecules are also known to play 
important roles in the immune response to PD.2 
For this purpose, we evaluated the effects of ozone 
treatment on oxidants and AOs by assaying levels of 
TOS, NO, 8-OHdG, MDA, GSH, and TAS in saliva to 
investigate the ozone effects on the immune response 
in PD. According to our findings, although increase in 
AO levels and decrease in oxidant levels were more 
pronounced in the ozone-treated group, no statistically 
significant differences were observed for any specific 
clinical parameters. These findings suggest that 
the stimulatory effects of ozone administration on 
periodontal tissues may be limited.
In addition, TGF-β levels were evaluated as a 
biochemical marker for tissue recovery. Previous 
studies have reported that an increase in TGF-β 
levels was associated with a decrease in periodontal 
inflammation, leading to improved outcomes.40 We 
did observe that TGF-β levels increased significantly 
in the ozone-treated group, supporting the claim that 
gaseous ozone treatment increases the regeneration 
activity of periodontal tissues. The difference in 
TGF-β levels could indicate that ozone therapy can 
contribute to periodontal treatment; however, we 
found that clinical recovery and changes to biochemical 
parameters were similar for both groups, confounding 
this result. The ozone application effect on whole 
oxidant and AO levels may be limited due to multiple 
factors involved in immune response and recovery.
Follow-up was limited to one month after second 
treatment application, which did not permit the 
evaluation of long-term periodontal outcomes. 
Although this period was beneficial in terms of 
eliminating the differences in hygiene practices among 
the patients and evaluating the short-term host 
responses, further studies on the long-term effects 
of ozone treatment on PD are needed.
Conclusion
SRP plus ozone application in periodontal pockets 
demonstrated similar effects as SRP alone in clinical 
recovery indicators and changes to biochemical 
markers. However, further research on the differential 
effects of ozone parameters, such as dosage, duration, 
and usage frequency in periodontal healing is needed.
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